Please note that due to a high volume of submissions, the ANZCTR is currently experiencing a delay in processing of submissions.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00164060




Registration number
NCT00164060
Ethics application status
Date submitted
13/09/2005
Date registered
14/09/2005
Date last updated
5/12/2013

Titles & IDs
Public title
Associations, Outcomes and Genomics of GB Virus C, Hepatitis C Virus and Human Immunodeficiency Virus Infection
Scientific title
Associations, Outcomes and Genomics of GB Virus C, Hepatitis C Virus and Human Immunodeficiency Virus Infection
Secondary ID [1] 0 0
35/04
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hepatitis C 0 0
HIV Infections 0 0
Condition category
Condition code
Infection 0 0 0 0
Studies of infection and infectious agents
Infection 0 0 0 0
Other infectious diseases
Infection 0 0 0 0
Sexually transmitted infections
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Infection 0 0 0 0
Acquired immune deficiency syndrome (AIDS / HIV)

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Comparator / control treatment
Control group

Outcomes

Eligibility
Key inclusion criteria
1. Sera available and appropriate for testing, including serial sera over a period of
time (retrospective analysis)

2. HIV serology positive.

3. Unequivocal HCV antibody positive or HCV RNA positive.
Minimum age
18 Years
Maximum age
80 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Those without sera available.

2. Those unwilling to give informed consent.

3. Persons with hepatitis B virus infection, as defined by the presence of hepatitis B
surface antigen and/or hepatitis B virus DNA positive.

Study design
Purpose
Duration
Selection
Timing
Retrospective
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Alfred Hospital - Melbourne
Recruitment postcode(s) [1] 0 0
3181 - Melbourne

Funding & Sponsors
Primary sponsor type
Other
Name
Bayside Health
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to examine the effect of GB virus C (GBV-C) on the natural
history of chronic hepatitis C virus (HCV) infection in subjects co-infected with HIV and
HCV. The other aspect of the study is to assess the effect of GBV-C on the severity of liver
disease due to chronic hepatitis C in subjects co-infected with HIV and HCV. This will be
done by determining the point prevalence of co-infection retrospectively then following that
cohort prospectively. In addition, further individuals will be recruited in a prospective
manner.
Trial website
https://clinicaltrials.gov/show/NCT00164060
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Mark D Berzsenyi, MBBS
Address 0 0
Alfred Hospital/Bayside Health
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT00164060